Zymeworks (ZYME) Revenue & Revenue Breakdown
Zymeworks Revenue Highlights
0
Latest Revenue (Q)
$16.00M
Main Segment (Y)
Research Support Payments And Other Service
Zymeworks Revenue by Period
Zymeworks Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $412.48M | 1446.03% |
| 2021-12-31 | $26.68M | -31.50% |
| 2020-12-31 | $38.95M | 31.84% |
| 2019-12-31 | $29.54M | -44.28% |
| 2018-12-31 | $53.02M | 2.43% |
| 2017-12-31 | $51.76M | 370.18% |
| 2016-12-31 | $11.01M | 13.96% |
| 2015-12-31 | $9.66M | 478.44% |
| 2014-12-31 | $1.67M | - |
Zymeworks generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Zymeworks Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $16.00M | -16.85% |
| 2024-06-30 | $19.24M | 91.85% |
| 2024-03-31 | $10.03M | -40.74% |
| 2023-12-31 | $16.93M | 2.54% |
| 2023-09-30 | $16.51M | 135.73% |
| 2023-06-30 | $7.00M | -80.32% |
| 2023-03-31 | $35.58M | -91.16% |
| 2022-12-31 | $402.49M | 15198.10% |
| 2022-09-30 | $2.63M | -51.65% |
| 2022-06-30 | $5.44M | 184.03% |
| 2022-03-31 | $1.92M | -90.36% |
| 2021-12-31 | $19.87M | 352.10% |
| 2021-09-30 | $4.39M | 148.16% |
| 2021-06-30 | $1.77M | 175.00% |
| 2021-03-31 | $644.00K | -95.89% |
| 2020-12-31 | $15.68M | 493.27% |
| 2020-09-30 | $2.64M | -78.61% |
| 2020-06-30 | $12.36M | 49.46% |
| 2020-03-31 | $8.27M | 340.54% |
| 2019-12-31 | $1.88M | -76.12% |
| 2019-09-30 | $7.86M | -0.28% |
| 2019-06-30 | $7.88M | -33.90% |
| 2019-03-31 | $11.93M | -58.77% |
| 2018-12-31 | $28.93M | 1308.23% |
| 2018-09-30 | $2.05M | -90.66% |
| 2018-06-30 | $22.00M | 54900.00% |
| 2018-03-31 | $40.00K | -99.92% |
| 2017-12-31 | $50.07M | 41976.47% |
| 2017-09-30 | $119.00K | -91.13% |
| 2017-06-30 | $1.34M | 483.48% |
| 2017-03-31 | $230.00K | -89.70% |
| 2016-12-31 | $2.23M | 2.76% |
| 2016-09-30 | $2.17M | -65.76% |
| 2016-06-30 | $6.34M | 2320.99% |
| 2016-03-31 | $262.00K | - |
Zymeworks generated $16.00M in revenue during Q3 2024, up -16.85% compared to the previous quarter, and up 228.51% compared to the same period a year ago.
Zymeworks Revenue Breakdown
Zymeworks Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| Research Support Payments And Other Service | $52.62M | $8.20M |
| Licensing Fee | - | $5.00M |
Latest
Zymeworks's latest annual revenue breakdown by segment (product or service), as of Dec 23: Research Support Payments And Other Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 |
|---|---|---|---|---|---|---|---|---|---|
| Milestone Revenue | $2.50M | $8.00M | - | - | - | - | - | - | - |
| Research Support Payments And Other Service | $764.00K | $1.11M | $2.07M | $10.04M | $538.00K | $1.16M | - | - | - |
| Upfront Fee | - | - | - | $18.00M | $18.00M | - | - | - | - |
| Milestone Payment | - | - | - | - | - | - | - | $1.00M | - |
| License and Service | - | - | - | - | - | - | - | $5.50M | - |
| Other Product | - | - | - | - | - | - | - | - | $2.63M |
Latest
Zymeworks's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Milestone Revenue (76.59%), and Research Support Payments And Other Service (23.41%).
Zymeworks Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| ALEC | Alector | $97.06M | $15.08M |
| YMAB | Y-mAbs Therapeutics | $84.82M | $18.46M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
| MRSN | Mersana Therapeutics | $36.85M | $12.60M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |
| BLUE | bluebird bio | $3.60M | $16.10M |
| ARWR | Arrowhead Pharmaceuticals | $3.55M | - |
| EDIT | Editas Medicine | - | - |
| ZYME | Zymeworks | - | $16.00M |
| CABA | Cabaletta Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| INZY | Inozyme Pharma | - | - |
| ANNX | Annexon | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| TERN | Terns Pharmaceuticals | - | - |
| ZNTL | Zentalis Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |